Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot short-duration therapy for acute hepatitis C genotypes 1 or 4 in HIV-infected patients with grazoprevir/elbasvir
2016-001125-13Phase 2Completed
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of grazoprevir in acute hepatitis C (HCV) and hepatitis C virus infection, sponsored by Institut de Médecine et d'Epidémiologie Appliquée. Primary endpoint: SVR12. Started Jun 2017; status: completed.
02
Drugs
grazoprevir
03
Conditions
acute hepatitis C (HCV)hepatitis C virus infection
Beyond the preview
Go deeper on 2016-001125-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001125-13.